Protocol Ledger

NCT06976476 · Phase II · RECRUITING

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Interventional Phase II clinical trial protocol NCT06976476 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-08 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06976476
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06976476
Protocol FieldVerified Registry Value
NCT IdentifierNCT06976476
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2025-05-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06976476
Hospital Research SiteLocationSite Profile
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI